ArticleRegenerative engineering and translational medicine2025
Role of FGF2 in promoting osteogenic differentiation for craniofacial bone regeneration.
Article in Regenerative engineering and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Fibroblast growth factor II (FGF2), or basic fibroblast growth factor (bFGF), is an important regulator in bone and craniofacial development. FGF2 regulates cell survival, proliferation, migration, multilineage differentiation, and stemness in stromal cells. While there is broad interest in utilizing FGF2 for bone and craniofacial tissue repair and regeneration, the literature and reported data are often inconsistent or even controversial due to its multifunctional nature. Therefore, the outcomes are dependent on dose, duration, timing of administration, spatiotemporal pattern of the FGF2 delivery, and the microenvironment. This review paper aims to discuss FGF2 signaling and its related pathways, as well as mechanisms
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.